These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role? Labrador-Horrillo M; Selva-O'Callaghan A J Rheumatol; 2018 Jun; 45(6):731-732. PubMed ID: 29858454 [No Abstract] [Full Text] [Related]
27. A potential biomarker for anti-PD-1 immunotherapy. Goswami S; Basu S; Sharma P Nat Med; 2018 Feb; 24(2):123-124. PubMed ID: 29414936 [No Abstract] [Full Text] [Related]
28. Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy? Saleh K; Khalifeh-Saleh N; Kourie HR; Nasr F; Chahine G Immunotherapy; 2018 Mar; 10(3):163-165. PubMed ID: 29370724 [No Abstract] [Full Text] [Related]
29. [Current challenges with PD-L1 testing for immunotherapy biomarkers in non-small cell lung cancer]. Li Y; Chen J Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):585-589. PubMed ID: 31422587 [TBL] [Abstract][Full Text] [Related]
30. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Sanmamed MF; Chen L Cell; 2018 Oct; 175(2):313-326. PubMed ID: 30290139 [TBL] [Abstract][Full Text] [Related]
31. Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy. Reading JL; Quezada SA Immunity; 2016 Dec; 45(6):1181-1183. PubMed ID: 28002724 [TBL] [Abstract][Full Text] [Related]
32. Making cancer immunotherapy a surer bet. Eisenstein M Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218 [No Abstract] [Full Text] [Related]
33. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224 [TBL] [Abstract][Full Text] [Related]
34. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells. Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843 [No Abstract] [Full Text] [Related]
35. There and back again: An immunotherapy tale. Guo Y; Krupnick AS J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610 [No Abstract] [Full Text] [Related]
37. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722 [TBL] [Abstract][Full Text] [Related]
38. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. Wang Y; Ma R; Liu F; Lee SA; Zhang L Front Immunol; 2018; 9():374. PubMed ID: 29556232 [TBL] [Abstract][Full Text] [Related]
39. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy. Ni JM; Ni AP Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108 [TBL] [Abstract][Full Text] [Related]
40. Editorial: Emerging Immunotargets in Genitourinary Tumors. Montironi R; Santoni M; Massari F; Lopez-Beltran A; Cheng L; Berardi R; Scarpelli M Curr Drug Targets; 2016; 17(7):748-9. PubMed ID: 27086839 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]